Delivering Lifesaving Medicines to Patients through Innovation, Regulatory Reform and Global Partnership

Sunday, June 25, 2017

Wayne T. Hockmeyer Auditorium

MedImmune, A Member of the AstraZeneca Group

1 MedImmune Way, Gaithersburg, MD 20878

Preliminary Program

7:30 AM – 8:30 AM  Registration and Continental Breakfast; Exhibition Booth Setup

8:30 AM – 8:35 AM  Welcome to the 22nd CBA Annual Conference

Dong Shen, M.D., Ph.D., President-elect of CBA

8:35 AM – 8:55 AM  Opening Remarks

8:35 AM – 8:40 AM  John C. Wobensmith, Secretary of State of Maryland

8:40 AM – 8:45 AM  Benjamin H. Wu, Deputy Secretary of the Maryland Department of Commerce

8:45 AM – 8:50 AM  Bahija Jallal, Ph.D., EVP of AstraZeneca, Head of MedImmune, a Member of the AstraZeneca Group

8:50 AM – 8:55 AM  Embassy of the People Republic of China in the USA

8:55 AM – 9:00 AM  Introduction of the CBA Life Achievement Awardees

Xu-Rong Jiang, M.D., Ph.D., President of CBA

9:00 AM – 9:30 AM  Lifetime Achievement in Research Award Presentation

Dr. Craig Venter, Co-Founder, Executive Chairman, Head of Scientific Strategy – Human Longevity, Inc., Founder, Chairman, and CEO of the J. Craig Venter Institute, Co-Founder, Executive Chairman, and Co-Chief Scientist of Synthetic Genomics Inc.

9:30 AM – 10:00 AM  Lifetime Achievement in Regulatory Science Award Presentations

Dr. Robert Temple, Deputy Director of Clinical Science, FDA CDER

10:00 AM–10:15 AM  Coffee Break and Refreshments

10:15 AM–11:15 AM  Session 1: Regulatory Innovations at FDA and CFDA: An Opportunity for A Strategic Collaboration

Session Co-chairs: Jingyu (Julia) Luan, Ph.D., FDA, John FinkBohner, Ph.D., AstraZeneca

10:15 AM–10:35 AM  Evolution of FDA Pharmaceutical Quality Oversight
10:35 AM – 10:55 AM  Updates on CFDA Drug Regulatory Reform
Xinyu Weng, P.D., Representative of CFDA in US, First Secretory of the Embassy of China in US

10:55 AM–11:15 AM  Session 1 Panel Discussion
Panelists:
Dr. Robert Temple, Deputy director of Clinical Science, FDA CDER
Dr. Ning Li, Vice President and Head of Region Asia and China Regulatory and Medical Policy in Sanofi
Dr. Helen Mao, Co-founder and Senior VP of CanSino Biologics Inc.
Dr. Lawrence X. Yu, Deputy Director, Office of Pharmaceutical Quality, FDA/CDER
Dr. Xinyu Weng, Representative of CFDA in US, First Secretory of the Embassy of China in US

11:15 AM–12:30 PM  Session 2: Global Collaboration
Session Co-chairs: Ziping Wei, Ph.D., Chief Executive Officer, BridgeBio, LLC, Jenny Zhao, Salubris
11:15 AM–11:30 AM  Honorable Mayor Dengxi Wang, Henan Xinxiang delegation
11:30 AM–11:45 AM  Mr. Xiang Xian Shao, Shanghai Naili Liuti Equipment Limited Company
11:45 AM–12:00 PM  Mrs. Sofia Sun, Marketgene Capital
12:00 PM–12:15 PM  Dr. John Li, Salubris
12:15 PM–12:30 PM  Dr. Kaifeng Wang, China Recourses Life Science Industry Development Co., Ltd
12:30 PM –1:30 PM  Luncheon

Afternoon Sessions
1:30 PM – 2:30 PM  Session 3: Precision Medicine
Session Chairs: Chuanhua Julia Xing, Ph.D., Founder, XPrecision
1:30 PM – 1:50 PM  Human genome project and the harmony of the society
Dr. Guoping Zhao, Executive director of the Chinese National Human Genome Center at Shanghai (CHGCS) and director of the National Engineering Center for BioChip
1:50 PM – 2:10 PM  Sequencing Seattle: Solve Population Health Challenges with Precision Medicine
Dr. Yiwu He, Global Head of R&D at BGI, CEO of BGI Groups USA
2:10 PM – 2:30 PM  Precision Medicine Calls For Precision Sequencing
Dr. Stephen Turner, Co-founder and Chief Technology Officer, Pacific Biosciences

2:30 PM – 2:45 PM    Break

2:45 PM – 3:45 PM    Session 4 Panel discussion: Entrepreneur Adventures of CBA Leaders
Session Chairs: Patrick Lu, Ph.D., Chairman of the Board and CEO, Sirnaomics, Inc.
Panelists:
Dr. Patrick Lu, Chairman of the Board and CEO, Sirnaomics, Inc.
Dr. Weiwu He, Chairman of the Board and CEO, Origene
Dr. Dajun Yang, Chairman of the Board and CEO, Ascentage Pharma

3:45 PM – 4:00 PM    Coffee Break and Refreshments

4:00 PM – 5:00 PM    Session 5 Panel Discussion: The Relationship between Investor and Entrepreneur
Session Chairs: Lin Sun-Hoffman, Ph.D. JD, Founding Partner at Liu, Zheng, Chen & Hoffman LLP
Panelists:
Dr. Henry Hsu, Founder and CEO, Alloysta Pharmaceuticals
Dr. Jimmy Zhang, Chief Executive Officer, Shenzhen CLI Life Science Investment
Dr. Ruhong Jiang, Chief Executive Officer, Applied Stem Cell
Dr. Weiwu He, Chairman of the Board and CEO, Origene

5:00 PM – 6:00 PM    Session 6: CBA-SCBA Joint Session - Cell signaling and human diseases
Session Co-chairs: Wang Xinwei, Ph.D., Senior Investigator, Chief, Liver Carcinogenesis Section, Deputy Chief, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Yali Fu, Ph.D., NIH

5:00 PM – 5:15 PM    Unconventional protein secretion in health and disease
Dr. Yihong Ye, Senior Investigator, NIH

5:15 PM – 5:30 PM    Targeting metabolic deficient pathway for cancer therapy
Dr. Chunzhang Yang, Investigator, NCI

5:30 PM – 5:45 PM    Proteomic Instability of Cancer: HSF1 is a Guardian of Cancer Proteostasis
Dr. Chengkai Dai, NIH Stadtman Investigator, Head, Proteomic Instability of Cancer Section, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute

5:45 PM – 6:00 PM    Session 6 Panel Discussion
Panelists:
Dr. Yihong Ye, Senior Investigator, NIH
Dr. Chunzhang Yang, Investigator, NCI
Dr. Chengkai Dai, NIH Stadtman Investigator, Head, Proteomic Instability of Cancer Section, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute

6:00 PM – 6:30 PM  The Situation and New Policy of Pharmaceutical Industry in China
Dr. Mingde Yu, Honorary Chairman of Chinese Biopharmaceutical Enterprises Association

6:30 PM  Closure of Exhibition
6:30 PM  Evening Reception